EcoDrugPlus

Phospholipase A2 Group X

Ensembl ID : ENSDCDG00000029697
Gene Symbol: PLA2G10
3 Cross references
175 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSDCDG00000018061
Gene Symbol: LOC114793326
3 Cross references
231 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSDCDG00000002929
Gene Symbol: GART
3 Cross references
214 Possible Orthologues:

Plasminogen

Ensembl ID : ENSDCDG00000029112
Gene Symbol: PLG
1 Cross references
252 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSDCDG00000004238
Gene Symbol: PLAT
3 Cross references
207 Possible Orthologues:

Plasminogen-Like

Ensembl ID : ENSDCDG00000029147
Gene Symbol: LOC114763571
3 Cross references
252 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSDCDG00000026299
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSDCDG00000026545
Gene Symbol: LOC114767881
3 Cross references
199 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSDCDG00000035619
Gene Symbol: LOC114791883
2 Cross references
174 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSDCDG00000002694
Gene Symbol: PLK1
3 Cross references
187 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSDCDG00000002265
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSDCDG00000034290
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).